Merck & Company, Inc. vs Zimmer Biomet Holdings, Inc. — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
ZBH
Zimmer Biomet Holdings, Inc.
$82.90
▲ 0.57%
Q·Score Winner
Zimmer Biomet Holdings, Inc.
ZBH6.9/10vs 6.7/10

Q·Score Breakdown

6.7
Neutral
Overall
6.9
Neutral
6.2
Quality
6
7
Health
7.6
6.2
Growth
8.8
7.2
Valuation
7.1
7.1
Sentiment
4.8
MRK

Forward P/E of 11.5× is low relative to sector peers.

ZBH

Earnings growing 34% year-over-year on 9% revenue growth.

cautious analyst consensus — few Buy ratings.

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
HOLD
Target $98.52 (+18.8%)
21 analysts

Fundamentals

MRK
ZBH
31.5×
Trailing P/E
21.5×
11.5×
Forward P/E
9.2×
13.6%
Profit Margin
9.1%
76.6%
Gross Margin
70.2%
ROE
6.1%
4.9%
Revenue Growth
9.3%
Earnings Growth
34.1%
0.28
Beta
0.61
Price / Book
$277.0B
Market Cap
$16.0B
$73 – $125
52-Week Range
$80 – $108

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →